Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4 + FOXP3 + Helios + thymic-derived Tregs and CD4 + FOXP3 + Helios 2 T cells, followed by comparison with CD4 + FOXP3 2 Helios 2 T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4 + CD25 + CD127 lo/2 T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226 + TIGIT 2 population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease. The Journal of Immunology, 2015, 195: 000-000.
T he adaptive immune system provides the host with a vast receptor repertoire of T and B cells that facilitate protection from a wide array of pathogenic microbes. One consequence of this incredible diversity is the development of T and B cells specific for self-tissues (1) . To counteract this autoreactivity, the immune system uses a number of mechanisms to reinforce peripheral immune tolerance, including a dominant role for a small population of CD4 + regulatory T cells (Tregs) (2) . The requirement for regulation is most apparent in individuals presenting with a mutation in the Treg lineage transcription factor FOXP3, which results in fatal autoimmune disease (3) .
Tregs exert their suppressive properties through a host of tolerogenic enzymatic pathways, cytokines, and the expression of multiple negative regulators (4) . Of these, CTLA-4 and PD-1 regulate T cell activation through interactions with APCs and host tissues (5) . Moreover, it is apparent that Tregs, like their Th counterparts, exhibit some level of lineage heterogeneity (6) (7) (8) , as well as the potential for cellular plasticity in response to environmental cues (9) . Deficiencies in Treg frequency and/or function have been associated with autoimmune diseases (10) . Notably, we reported an increase in IFN-g + Helios 2 Tregs with reduced suppressive capacity in type 1 diabetes (T1D) (11) . An analogous finding was also reported in patients with MS (12) . Unstable function has also been observed at a single-cell level, with IL-17-producing FOXP3 + Tregs exhibiting some suppressive capacity that was attenuated in the presence of inflammatory cytokines (13) . Collectively, these studies raise the intriguing potential that subsets of Ag-experienced Tregs may contribute to defective immune regulation in the context of inflammation and autoimmune disease (9) .
The ability to preserve and/or bolster the activity of Tregs is now appreciated as being key for inhibiting autoimmune reactivity (14) . These studies have generally focused on two subsets of Tregs. Thymic-derived Tregs (tTregs) express the transcription factors FOXP3 and Helios and are demethylated at the FOXP3-Treg-specific demethylated region (TSDR) (15) . In contrast, peripherally induced Tregs develop from naive T cells under tolerogenic conditions and are minimally demethylated at the TSDR (16) .
To further characterize the diversity of Tregs, we conducted a transcriptional profile of human T conventional cells (Tconvs), FOXP3 + Helios 2 T cells, and FOXP3 + Helios + tTreg subsets. Through this analysis, we demonstrate that the coinhibitory molecule TIGIT is highly expressed in tTregs. TIGIT competes with the costimulatory molecule CD226 for binding to the poliovirus receptor/Nectin-like-5/CD155 prominently expressed on APCs (17) . CD226 has been identified as an autoimmune susceptibility gene, with a single nucleotide polymorphism (Gly 307 Ser; rs763361) linked to T1D, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Wegner's granulomatosis, celiac disease, and juvenile idiopathic arthritis (18, 19) . This recently described axis shares many parallel functions with the CD28-CTLA-4 pathway in terms of promoting or inhibiting T cell activation, respectively (20) (21) (22) . Activation of CD226 leads to TCR association and activation that promotes Th1-related signaling (22, 23) . Phosphorylation of the tyrosine at residue 322 results in IFN-g secretion and proliferation (24) . In contrast, TIGIT contains an inhibitory ITIM that leads to SHIP1 recruitment and downmodulation (20, 25) . Ligation of TIGIT with an agonistic Ab has been shown to suppress activation (22) .
TIGIT has recently been associated with Treg biology through transcriptional profiling of Tregs (8, 21, 26, 27) , and has also been characterized as highly demethylated in FOXP3 + T cells (28) . In addition to intrinsic inhibitory activity, TIGIT binding to CD155 on dendritic cells leads to a reduction in IL-12p40 and a concomitant increase in IL-10 production (29) . Importantly, TIGIT attenuates antitumor immunity by CD8 + T cells (30) , and it was recently demonstrated as a mechanism by which Tregs exert their suppressive activity (31) .
Despite the roles of this costimulatory axis in immunoregulation, little is known about the cellular distribution and phenotype of human Tregs expressing CD226 and TIGIT. In this study, we sought to address this knowledge void and specifically understand the role of TIGIT and CD226 in Treg biology. To that end, we isolated subsets of CD4 + CD25 + CD127 2/lo Tregs expressing CD226 and/or TIGIT, and expanded them ex vivo to assess their phenotype and suppressive capacity. We demonstrate that production of IFN-g within Tconvs and Tregs is tightly linked to coexpression of CD226. Conversely, selection of CD226 2 Tregs, irrespective of initial TIGIT expression, leads to a suppressive population of tTregs that are demethylated at the TSDR.
Materials and Methods
Sample procurement and processing ) were sorted into RNALater (Life Technologies). RNA was extracted with the RNeasy FFPE Kit (Qiagen) by proteinase K digestion followed by incubation at 80˚C. RNA quality was verified on a Bioanalyzer (.300 bp length for .50% of transcripts) with the RNA Nano Chip (Agilent Technologies). RNA transcripts (100 ng) were directly quantified with the nCounter and the Human Immunology GX Panel (v1; NanoString Technologies).
Flow cytometry and FACS
All samples were first stained with Fixable Live/Dead Yellow or Near IR (Invitrogen). Surface markers were analyzed immediately after staining or after fixation with BD Cytofix (BD Biosciences). Cells were stained for intracellular proteins in FOXP3 fixation and permeabilization buffers according to the manufacturer's protocol (Biolegend). Abs used included CD4-Pacific Blue (RPA-T4), TIGIT-APC or -PerCP-eFluor710 (MBSA43; eBioscience), CD4-PE-CF594 (RPA-T4), CD45RO-APC (UCHL1) and CD8 (SK1; BD Biosciences), CXCR3-PerCP-Cy5.5 (G025H7), CCR4-PECy7 (TG6/CCR4), CCR6-BV605 (G034F3), CD226-PE (11A8), CD127-PE or -BV421 (A019D5), CD25-APC or -Alexa Fluor (AF) 488 (BC96), IFN-g-PE-Cy7 (4S.B3), Helios-PE or -Pacific Blue, -AF647 (22F6), and FOXP3-AF488 and -PE (206D) (Biolegend).
Cytometric analyses were performed on a LSR Fortessa (BD Biosciences). Data were collected using BD DIVA acquisition software and imported into FlowJo (v9.7.5; Tree Star) for analysis. Marker positivity was determined by fluorescence minus one method. Expression levels were calculated with geometric mean fluorescence intensity (gMFI).
Cell sorting was conducted on a FACSAria III (BD Biosciences).
2 ) and Tconvs (CD4 + CD127 + ) were further enriched based on CD226 and/or TIGIT expression. Postsort purities were typically .93% (median 93%; range 90-95%).
In vitro T cell expansion and activation cultures
Tregs and Tconvs were expanded as previously described (32) . After expansion, cells were analyzed for intracellular IFN-g by reactivation for 4 h with PMA (10 mg/ml) and ionomycin (500 nM) in the presence of GolgiStop (4 ml/6 ml culture; BD Biosciences). For multiplex cytokine detection, cells were activated with anti-CD3-and anti-CD28-coated dynabeads (Life Technologies) according to manufacturer recommendations, and supernatants were collected at 24, 48, and 72 h.
Suppression assays
Expanded Treg subsets were tested for their ability to suppress autologous T cell proliferation, as described previously (33) , with the following modifications. Tregs were labeled with CFSE (0.15 mM), whereas responding cells were stained with Cell Trace Violet (2.5 mM; Life Technologies) and activated with either autologous APCs or Treg Suppression Inspector beads (Miltenyi Biotec). Triplicate cultures were harvested and pooled after 96 h, stained with live/dead dye, CD4, CD8, CD226, and TIGIT, and proliferation was calculated by division index of gated live lymphocytes.
Analysis of the FOXP3-TSDR
TSDR demethylation at the conserved noncoding region 2 of FOXP3 is a hallmark of lineage-stable tTregs (34) . Nucleotides were isolated with AllPrep DNA/RNA Mini Kit (Qiagen) or DNeasy tissue kit (Qiagen), as appropriate. Bisulfite treatment of genomic DNA was performed on 500 ng DNA with the EZ DNA Methylation Kit (Zymo Research).
Real-time PCR was performed to determine the methylation status at the FOXP3-TSDR for each sample. DNA standards originated from unmethylated bisulfite-converted human EpiTect control DNA (Qiagen) or universally methylated bisulfite-converted human control DNA (Zymo Research). To obtain a large quantity of standard, we PCR-amplified the TSDR using the following reaction: 50 ml reaction volume containing 25 ml of ZymoTaq PreMix buffer (Zymo Research) and 0.5 mM each of the primers FOXP3_TSDRfwd (59-ATATTTTTAGATAGGGATATGGAGAT-GATTTGTTTGG-39) and FOXP3_TSDRrev (59-AATAAACATCACCT-ACCACATCCACCAACAC-39). After incubation at 95˚C for 10 min, amplification was performed as follows: 50 cycles at 95˚C for 30 s, 55˚C for 30 s, and 72˚C for 1 min. Amplified PCR products were purified with the QIAquick Gel Extraction Kit (Qiagen). The concentration of purified control TSDR DNA was determined with a GE NanoVue spectrophotometer (GE Healthcare Life Sciences).
TSDR real-time PCR was performed with probes that targeted methylated or demethylated target sequences. The reaction was performed in 384-well white trays with a Roche LightCycler 480 system (Roche Diagnostics). Each reaction contained 10 ml LightCycler 480 Probes Master Mix (Roche), 1 ml bisulfite converted DNA sample or standards, 1 mM of each primer, and 150 nM of each probe with a final reaction value of 20 ml. The probes used for amplification were TSDR-Forward 59-GGTTTGTATTTGGGTTTTGTTGTTATAGT-39 and TSDR-Reverse 59-CTATAAAATAAAATATCTACCCTCTTCTCTTCCT-39. The probes for target sequence detection were FAM-labeled methylated probe, FAM-CGGTCGGATGCGTC-MGB-NFQ, or VIC-labeled unmethylated probe, VIC-TGGTGGTTGGATGTGTTG-MGB-NFQ. All samples were tested in triplicate. The protocol for real-time amplification is as follows: after initial denaturation at 95˚C for 10 min, the samples were subjected to 50 cycles at 95˚C for 15 s and at 61˚C for 1 min. Fourteen different ratios of fully methylated and demethylated template were used as real-time standards. A six-order polynomial equation was used to extrapolate the percentage of cells demethylated at the TSDR for each sample.
T cell transcriptional profiling
Using the nSolver Analysis Software (NanoString), counts were first normalized to the geometric mean of the positive control spiked into the assay, then normalized to 10 housekeeping genes built into the array. Subsequent analyses were conducted with the Partek Genomic Suite (Partek). The signal-to-noise ratio was significantly higher in the expanded T cell counts compared with the fixed cell sorted T cell counts. Thus, two different statistical approaches were used.
For the mRNA count data from fixed cells, counts were normalized to the 10 internal housekeeping genes, and the average of the background counts (noise) was subtracted with values lower than background set to 1. The fold change was calculated by taking the geometric mean of the counts, then dividing one subset by another. A paired ANOVA coupled with the Bonferroni multiple test correction (MTC) was used to determine differentially regulated genes with a significance value of p , 0.05. Complete gene expression data can be found by accessing Gene Expression Omnibus [GEO] accession number: GSE61834; http://www.ncbi.nlm.nih.gov/geo/).
For the mRNA from expanded cells, genes that were below the background threshold (mean of negative controls count + 2 SDs) for both Tregs and Tconvs were removed from the analysis. Because Tconvs often have a variance different from Tregs at both the RNA and the proteins levels, a Welch's ANOVA with a Bonferroni MTC was used to determine significance (p , 0.05). Significantly regulated genes with a false discovery rate ,0.05 were normalized around zero and clustered using the average of the means. Eighty-two genes were identified as being differentially expressed between the populations (GEO accession number GSE62015).
Isolation of IFN-g-producing Tregs
Tregs and Tconvs were FACS isolated from five healthy subjects (median age 26 y, range 22-30 y) and sorted into two groups. In brief, the first group was stimulated for 4 h with PMA/ionomycin and labeled with the IFN-g cytokine cell-capture reagent (Miltenyi Biotech) followed by FACS isolation of IFN-g 2 and IFN-g + populations, as previously described (11). The second set was expanded to day 14 before reactivation and cytokine cell capture.
For each sample, 25 ng total RNA was amplified using the Ovation Pico WTA System (NuGen) and labeled with Encore Biotin Module V2 (NuGen). GeneChip Human Genome U133 Plus 2.0 arrays (Affymetrix) were hybridized to 5 mg labeled, amplified cDNA, washed, stained, and scanned according to the protocol described in the GeneChip Expression analysis manual (GEO accession number GSE59786). Gene expression profiling data were extracted from the Affymetrix Microarray Suite 5.0 (MAS 5.0) software and used for subsequent statistical analyses.
Multiplex cytokine assay
Cytokine production was determined using the Human T H 17 Magnetic Bead Panel (HT17MG-14K-PX25; EMD Millipore) according to manufacturers' instructions from culture supernatants collected and run in duplicate. Samples were processed on a Bio-Tek ELx405, detected with MAGPIX system (EMD Millipore), and analyzed with Milliplex Analyst software.
Data analysis
An ANOVA with a post hoc Tukey MTC was used for analysis of cytometric data using Prism (v6; GraphPad). Geister-Greenhouse variance correction method was applied to the data to account for the difference in variance between Tregs and Tconvs, with values matched between each individual.
Results

TIGIT is enriched in tTregs
Human Tregs display a considerable degree of heterogeneity (15 Fig. 1A ), which then underwent direct mRNA hybridization that facilitates the direct quantitation of mRNA transcripts without reverse transcription and amplification. This approach is compatible with partially degraded RNA samples, such as those obtained from fixed samples (35) .
Patient-to-patient variance accounted for 77% of the expression differences observed between the samples; however, we identified genes putatively associated with Tregs, including CTLA-4 and IL2RA (Supplemental Table I ) (36) . Specifically, we found the mRNA levels of TIGIT to be 12.4 times greater in tTregs compared with Tconvs (p , 0.05; Fig. 1B ). In addition, our analysis demonstrated strong coexpression of TIGIT and Helios in CD4 + FOXP3 + T cells (Fig. 1C) . Our results are in line with prior reports suggesting that TIGIT expression is maintained by FOXP3 (28) and supports the notion that it may play an important role in immune regulation (20, 21, 29, 31) .
Given that TIGIT and CD226 compete for binding to the ligand CD155 (21, 22) , we analyzed their surface expression on CD4 + T cells in combination with FOXP3 and Helios (Fig. 2) . Strikingly, tTregs had the highest percentage of TIGIT + cells (83.4 6 6.2%) and did not express CD226 in the absence of TIGIT ( Fig. 2A) . In contrast, Tconvs coexpressed TIGIT only with high CD226 expression, suggesting TIGIT may play an important role in Tconvs after activation, as noted previously (22) . TIGIT expression by tTregs was increased in frequency and gMFI compared with FOXP3 + Helios 2 T cells, and the lowest frequency of TIGIT + cells and gMFI found in Tconvs (Fig. 2B, left graphs) . In contrast, CD226 expression was higher in Tconvs, followed by FOXP3 + Helios 2 , and then tTregs (Fig. 2B, right graphs) . 
Differentiated T cells concomitantly express high CD226 and chemokine receptors
Prior reports suggest signaling through CD226 suppresses Th2 differentiation and promotes Th1 responses and IFN-g secretion (22) . We sought to understand the cellular distribution and expression profiles of CD226 and TIGIT on human naive, central and effector memory, and T effector memory CD45RA + (TEMRA) subsets (Fig. 3A) . Although naive T cells were the most abundant population in our cohort (mean 6 SEM, 44.8 6 14.6%), they expressed the lowest surface levels of CD226 (495.4 6 73.5 gMFI), when compared with effector memory T cell (T EM ) and central memory T cell (T CM ) subsets (1785 6 357.2 and 3185 6 492.6, respectively; Fig. 3B ). Furthermore, the cellular distribution of CD226 in the bulk CD4 + T cell population demarcates naive (CD226 2/low ) versus CD226 hi memory subsets. Few naive cells express TIGIT (5.3 6 2.6%) compared with the memory subsets (29.0 6 3.5% for T EM and 32.7 6 8.2% for T CM ). Notably, one subject with a prominent TEMRA population was CD226 hi TIGIT 2 ( Fig. 3A) , which coincides with their role as a proinflammatory T cell subset (37) .
In addition to robust CD226 expression in T EM and T CM , we also noted that chemokine receptors expressed by Th2, Th17, and Th1 cells were coexpressed with high levels of CD226 (Fig. 3C, upper  plots) . TIGIT + populations also expressed chemokine receptors, albeit to a lesser extent than with CD226 (Fig. 3C, lower plots) . Increased CD226 and TIGIT on differentiated subsets were observed for both CD4 + CD127 + Tconvs and CD4 + CD25 + CD127
2/lo
Tregs (Fig. 3D ).
CD226 expression is associated with effector cytokine production CD226 and TIGIT have opposing roles in the regulation of IFN-g (22) . We sought to determine how CD226 and TIGIT influenced IFN-g production by PBMCs after activation (Fig. 3E) To determine whether this association was influenced by Th1-skewing conditions, we activated T cells in the presence of IL-12 (Supplemental Fig. 1 ). Although it has been previously shown that both CD226 and TIGIT increase upon T cell activation (22) , the change in TIGIT expression by tTregs has not been characterized after culture with IL-12. As shown previously, CD226 expression increased over the 72-h time course (Supplemental Fig. 1A) . Likewise, our data demonstrated that TIGIT increases after TCR activation (22) . Notably, we observed TIGIT upregulation was attenuated by IL-12 in FOXP3 + Helios + Tregs (Supplemental Fig. 1B) . IL-12 upregulated CD226 and IFN-g as expected (Supplemental Fig. 1C, 1D) ; however, the proportion of tTregs recovered from the culture decreased in IL-12 (Supplemental Fig. 1E ) (38) . These data suggest a mechanism whereby IL-12 exposure may potentiate Tconv cytokine production concomitant with a reduction in both tTreg proliferation and TIGIT expression.
Our prior studies demonstrated elevated IFN-g + Tregs in patients with T1D (11 (Fig. 3G) . Importantly, both freshly isolated and expanded IFN-g + Tregs express significantly more CD226 than the IFN-g 2 Treg subset (Supplemental Fig. 2A) . Moreover, TIGIT expression was increased in IFN-g 2 Tregs compared with IFN-g + Tregs, whereas the inverse is true for Tconvs (Supplemental Fig. 2B ).
CD226 and TIGIT identify functionally distinct subpopulations of Tregs
Human CD4 + CD25 hi CD127 2 Tregs contain a significant degree of heterogeneity in terms of lineage diversity and Ag exposure. We subdivided CD4 + CD25 hi CD127 2 Tregs (39) based on CD226 and TIGIT expression (Fig. 4A, right plot) . FOXP3-TSDR demethylation at the conserved noncoding sequence 2 has been previously associated with Treg stability (34, 40 (15, (41) (42) (43) . Therefore, we analyzed the purity and suppressive activity of Tregs post in vitro expansion based on CD226 and TIGIT expression (Fig. 5A) . Although the TIGIT + fractions constituted the majority of Tregs isolated from PBMCs, we observed these cells were highly refractory to expansion, limiting the overall Treg yield (Fig. 5A ). This decrease in proliferative capacity of the sorted TIGIT + Tregs supports the role of TIGIT as an intrinsic negative regulator (22) , and also reflects an enrichment of Agexperienced (CD45RO + ) cells with limited expansion capacity (32) . In contrast, the TIGIT 2 Treg fraction expanded robustly from a naive state.
To further assess the purity and functional capacity of these subsets, we analyzed FOXP3 and Helios after expansion (Fig. 5B,  5C ). The highest purity of postexpansion Tregs originated from cells lacking CD226 expression at the time of the initial sort (i.e., before in vitro expansion 11.70). Tconvs expanded with very little FOXP3 and Helios coexpression (Fig. 5B) . In terms of surface CD226 and TIGIT expression, TIGIT was maintained or upregulated on TIGIT + and TIGIT 2 CD226 2 cells after expansion but remained low on TIGIT 2 CD226 + Treg and Tconv populations (Fig. 5D, 5E ). We previously demonstrated that expanded Tregs from T1D subjects were enriched in FOXP3 + Helios 2 cells with the capacity to produce IFN-g (32) . Accordingly, CD226 + Tregs have increased capacity to produce IFN-g upon stimulation, whereas CD226
2 Tregs were almost completely devoid of IFN-g (Fig. 5F,   5G ). CD226 2 Tregs (TIGIT + or TIGIT 2 ) were both able to potently suppress autologous CD4 and CD8 T cell proliferation, with some diminution observed in the CD226 + expanded subset (Fig. 5H) . The CD226 2 TIGIT 2 and CD226 2 TIGIT + subsets were almost completely demethylated at the TSDR (92.0 6 3.13 and 94.5 6 3.71%, respectively; Fig. 5I ). The degree of demethylation at the TSDR correlated strongly with FOXP3 and Helios coexpression determined by FACS (R 2 = 0.94, p , 0.0001; Fig. 5I ).
CD226
+ TIGIT 2 T cells express an activated effector gene expression profile and produce IL-10 and effector cytokines
Gene expression profiles provide a powerful signature of the regulatory and effector mechanisms used by T cells (8) . Given that most Treg therapies will require some form of expansion, we conducted a gene profile on in vitro-expanded Tconvs (CD4 + CD25 2 CD127 + ) or Tregs (CD4 + CD25 + CD127 2/lo ) that were further subdivided based on initial TIGIT and CD226 expression (Fig. 6A) . From this analysis, we found 159 genes differentially expressed between the groups (p , 0.05). These data are summarized in the heat map and dendogram ( Fig. 6A and Supplemental Table II ). The normalized transcript counts were used to cluster the genes. About 18.6% of the variance observed was attributable to individual subject variance, whereas the remainder segregated based on the initial sorted populations. Tconvs showed a clear demarcation from Tregs, with the CD226 + TIGIT 2 population demonstrating an intermediate expression profile between Tregs and Tconvs (Fig. 6A, green bars) . Interestingly, the CD226 + TIGIT + population has a Treg signature highly enriched in negative regulators and immunoregulatory pathways (Fig. 6B-E) . Despite this regulatory signature, it did not completely correlate with their suppressive capacity after in vitro expansion (Fig. 5H) . This may imply that CD226 negatively impacts suppression, or may reflect a preferential outgrowth of non-Tregs by day 14, as indicated by the TSDR results (Fig. 5I) . PCA analysis of Treg subsets demonstrated the CD226 + TIGIT 2 population shared some common features with Tconvs (Fig. 6F ). An extensive multiplex cytokine profile of freshly isolated Tregs further confirmed the capacity of CD226 + TIGIT 2 T cells to produce a broad array of cytokines (Fig. 6G, 6H ).
Exclusion of CD226 + eliminates unstable Tregs after in vitro expansion
Improving Treg stability and limiting contamination non-tTregs may be critical for future Treg therapies (44) . Prior efforts demonstrated that CD226 expression, irrespective of initial TIGIT expression, resulted in a sizable fraction of cells that were reduced in suppressive activity and methylated at the TSDR (Fig. 5) . In addition, we noted that the TIGIT + population was highly refractory to expansion. Thus, we hypothesized that eliminating CD226 + cells during the initial sort would increase purity without significantly constraining the final cell yield (Fig. 7A) . We observed that total Tregs and CD226
2 Tregs expanded with comparable kinetics (Fig. 7B) . Importantly, the purity of the Treg Fig. 7C, 7D) . As noted previously, we again observed that CD226 expression correlated with IFN-g (Fig. 7E, 7F ). This observation was inversely related to TIGIT expression after culture (Fig. 7G, 7H ). In terms of suppressive capacity, CD226 2 Tregs were consistently more able to suppress CD4 + and CD8 + responder T cells than their CD226 + Treg counterparts (Fig. 7I) . Indeed, an increased ratio of TIGIT/ CD226 expression on the tTreg population after an in vitro suppression assay was associated with increased suppressive activity and TSDR demethylation (Fig. 7I-K [46] , and so on). It is intriguing to think this may also be the case for Ag-experienced Tregs that are CD226 + TIGIT + . In support of this, we noted lineageassociated chemokine receptor expression on both CD226-and TIGIT-expressing Tregs. TIGIT + CD226 2 Tregs expressed high levels of FOXP3 and Helios, and were demethylated at the TSDR. Moreover, data from in vitro suppression assays indicated TIGIT expression on Tregs was associated with robust suppressive activity. We would speculate the relative ratio of these receptors might provide an informative biomarker. These findings are particularly timely given the genetic associations of CD226 in autoimmune diseases (11, 12, 18) and multiple reports of Treg functional defects and effector cytokine production by Tregs (e.g., IFN-g and IL-17). Interestingly, analysis of IL-10-producing T regulatory type 1 cells also reported high CD226 expression, in addition to CD49b and LAG3 (47) . Immunotherapeutics targeting coinhibitory molecules such as CTLA-4 and PD-1 have garnered increasing interest following notable clinical successes (49) . Our findings raise important implications for future therapies that may seek to target the CD226/TIGIT axis. Our studies support prior reports that CD226 is associated with proinflammatory Tconvs (21, 50) . In addition, our data clearly demonstrate CD226 is also expressed at low to intermediate levels on naive T cells and may play a key role in IL-10-producing Tregs. Moreover, CD226 is upregulated on the majority of tTregs after activation. Thus, therapies seeking to block CD226 to attenuate Tconv activity must be carefully dosed to target CD226 hi -expressing Tconvs, whereas preserving naive T cells and IL-10-producing T regulatory type 1. Our results also suggest the CD226/TIGIT axis may be susceptible to control by innate inflammatory cytokines, as we demonstrated for IL-12. These findings suggest that one potential benefit of anti-IL-12 Ab therapy may be the preservation of TIGIT expression on tTregs. Finally, our study has implications for Treg adoptive cell therapies that are currently progressing in clinical trials for a number of autoimmune conditions (44) . Overall, our studies continue to support the notion that CD4 + CD25 + CD127 2/lo Tregs maintain a high degree of purity after expansion over a period of 14 d. Extending these findings, we demonstrated that the selection of the TIGIT + Treg population resulted in a highly enriched population, but this came at the cost of initial Treg recovery and resulted in a highly refractory population limiting the overall yield. However, our data also suggest that the isolation of CD226 2 Tregs, irrespective of initial TIGIT expression, results in a highly pure and potent population of TIGIT + Tregs for use in cell therapies. In summary, these data provide a biological context in which the autoimmune candidate gene CD226 may modulate T cell biology. Moreover, these studies provide markers to identify highly suppressive Tregs for use in cell therapies. 
